Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking,

Selvaraj, Divakar

Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking, [electronic resource] - Journal of biomolecular structure & dynamics Feb 2021 - 621-634 p. digital

Publication Type: Journal Article

1538-0254

10.1080/07391102.2020.1715261 doi


Androgen Receptor Antagonists--pharmacology
Furans
Humans
Lignans
Male
Molecular Docking Simulation
Molecular Dynamics Simulation
Prostatic Neoplasms--drug therapy
Prostatic Neoplasms, Castration-Resistant
Receptors, Androgen--genetics